- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
Patent holdings for IPC class A61P 19/04
Total number of patents in this class: 851
10-year publication summary
|
33
|
49
|
51
|
57
|
103
|
79
|
88
|
50
|
64
|
36
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10174 |
12 |
| The Regents of the University of California | 20868 |
11 |
| Mayo Foundation for Medical Education and Research | 3403 |
10 |
| Clementia Pharmaceuticals Inc. | 93 |
8 |
| Research Institute at Nationwide Children's Hospital | 644 |
7 |
| TCI Co., Ltd. | 294 |
7 |
| The Johns Hopkins University | 5929 |
6 |
| Chugai Seiyaku Kabushiki Kaisha | 1424 |
6 |
| Viking Therapeutics, Inc. | 65 |
6 |
| Boehringer Ingelheim International GmbH | 4488 |
5 |
| Agency for Science, Technology and Research | 3758 |
5 |
| Acceleron Pharma Inc. | 341 |
5 |
| Eli Lilly and Company | 4117 |
5 |
| Hiroshima University | 588 |
5 |
| National University Corporation Hokkaido University | 1384 |
5 |
| Osaka University | 3258 |
5 |
| Rhode Island Hospital | 201 |
5 |
| Kolon Tissuegene, Inc. | 41 |
5 |
| Biosplice Therapeutics, Inc. | 160 |
5 |
| Merck Patent GmbH | 5742 |
4 |
| Other owners | 724 |